A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merrimack Pharmaceuticals
• Treatments: Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Patients with locally advanced or metastatic non-small cell lung cancer.

• Patients must be >/= 18 years of age.

• Patients must have adequate Performance Status (PS) as measured by ECOG and adequate end organ function.

Exclusion Criteria:

• Patients with a recent history (within 5 years) of another malignancy.

• Patients who are pregnant or nursing.

• Patients with clinically significant heart failure.

• Patients with clinically significant eye or gastrointestinal abnormalities.